Introduction
Parkinson's disease (PD) is a chronic progressi ve neurodegenerative disease that affects 12% of the population older than 65 years [14] , diminishes quality of life and autonomy of patients [30] . Parkin son's disease is characterized by exacerbated loss of dopaminergic neurons of the substantia nigra pars compacta, which clinically expresses through tremor, rigidity, bradykinesia, postural instability and pro gressive impairment of the cognitive function [34] .
Genetic factors that confer susceptibility to PD are still unclear although genetic variants in mito chondrial and nuclear genomes have been involved in this disease [17, 37] ; however, genetic variants in sezzzveral candidate genes (PARK genes) have been investigated in relation to both late and early onset presentations of the disease [lateonset PD (LOPD) and earlyonset PD (EOPD), respectively). Among these genes, LRRK2 and PARK2 are the most associ ated to LOPD and EOPD forms, respectively [31] .
LRRK2 encodes a multidomain protein, "dard arin" with kinase and GTPase activities. One of the most widely studied genetic variants within LRRK2 is rs34637584 (c.6055G>A), (p.Gly2019Ser) located in the kinase domain [14, 26] . In vitro studies showed an increased phosphotransferase activity due to this change [9] . It is worth noting that p.Gly2019Ser is the most common genetic variant of LRRK2 in Caucasians; whereas another SNP, rs34778348 (p.Gly2385Arg) is considered a risk factor for PD in Asians [6, 18] . The p.Gly2385Arg change in the Cterminal domain of LRRK2 was shown to render neurons more suscep tible to apoptosis under oxidative stress [35] . Thus, both variants are considered pathogenic although with different magnitude and biochemical effect.
On the other hand, PARK2 encodes a protein named "PARKIN", a component of an enzyme complex within the ubiquitinproteasome system, which tar gets proteins for degradation [39] . Mutations in PARK2 are highly associated to familial EOPD; up to 18% of patients present mutations in this gene, and only 5% of them present in the homozygous state [21, 27] .
Interestingly, a skewed distribution of genetic variants of PARK genes was previously described; some authors suggested that ethnicity may play a role as a modifying factor of pathogenicity of LRRK2 variants [13, 19, 36] . Interestingly, some mitochondri al variants and haplogroups are thought to mod ify the risk of developing PD [15, 38] by decreasing or increasing the penetrance of genetic variants in nuclear diseasegenes (PARK genes). In this regard, it is known that the Mexican population was a result of genetic admixture among Amerindians, Caucasian and in a lesser extent, Africans [29] and, as in other Latin American populations [1] , genetic factors pre disposing to PD in Mexicanmestizos remain largely unknown [23, 28, 40] . Therefore, the aim of this study was to analyze the possible association between variants in PARK genes and PD by multiple screening as well as the weighing of their clinical relevance in Mexicanmestizo patients with sporadic PD (sPD).
Material and methods

Study population
The study was approved by the Human Research Committees of the participating institutions and informed written consent was obtained from all individuals. This is a crosssectional study in which twohundred fifteen Mexicanmestizo patients with sPD were consecutively recruited from February 2009 to June 2010, from four tertiarycare level hospitals in Mexico (Neurology Departments from Centro Médico Nacional "20 de Noviembre"ISSSTE, Centro Médico Nacional Siglo XXIIMSS, Instituto de Cien cias Médicas y de la Nutrición "Salvador Zubirán", Mexico City; and División de Genética, Centro de Investigación Biomédica de OccidenteIMSS, Jalisco, Mexico); nevertheless, 42 patients were eliminated because of incomplete data. The diagnosis of sPD was performed by an experienced neurologist, based on the Queen Square Brain Bank criteria [16] . Ear lyonset PD was defined as onset at the age of 20 to 40 years. Two hundred and eight healthy individuals (controls) were analyzed; all were of Mexicanmesti zo ethnic origin, and were blood bank donors and/or healthy spouses of PD patients without family histo ry of PD or other neurological diseases. Cases with secondary parkinsonism were excluded.
Mutation analysis
Peripheral blood samples were obtained from patients and genomic DNA was isolated by the CTABDTAB method [11] . Realtime polymerase chain reaction (PCR) allelic discrimination TaqMan assay (AB) was used for genotyping LRRK2 var iants. Briefly, PCR reactions contained 1020 ng of DNA, 5.0 µl of Maxima Probe qPCR Master Mix (2X), 0.25 µl of primers and probes (10X) and H 2 O to 10 µl, including the appropriate negative con trols in all assays. For the p.Gly2019Ser variant, the assay was available from Applied Biosystem (assay ID: C_63498123_10), whereas for thep.Gly2385Arg polymorphism a novel hydrolysis probe assay was designed by our group. Primers sequences were as follows: forward 5'GAAGTGTGGGATAAGAAAACTG3' and reverse 5'AGATGG TGCTGAGAAGCATTAC3'. The probe for each allele was: wildtype VIC 5'CTCTGT [G] GACTAATAGACTGCGTGCAC3' and mutant FAM 5'CTCTGT [A] GACTAATAGACTGCGTGCAC3'. Realtime PCR was performed on a LightCycler 480 II (Roche Dia gnostics GmbH, Switzerland). Conditions for p.Gly2019S er and p.Gly2385Arg p.Gly2385Arg polymorphisms were 95°C for 10 min, and 40 cycles of amplification (92°C for 15 s and 60°C for 1 min). For each cycle, the soft ware determined the fluorescent signal from the VIC or FAMlabelled probe (Roche Applied Science, Mannheim, Germany). In order to confirm results of realtime geno typing, DNA was amplified by PCR and then sequenced (conditions and sequence of primers can be found in supplementary material).
For the EOPD subgroup, MultiplexLigation Depen dent Probe Amplification (MLPA) was used to detect genetic variants in PARKIN (PARK2), PINK1 (PARK6), DJ-1 (PARK7), LRRK2 (PARK8), SNCA (PARK1/4) and ATP13A2 (PARK9) genes. The assay also detects gross gene deletions/duplications (P051kit MRCHolland) by direct hybridization and ligation of exonspecif ic half probes to DNA, ligated probes were further amplified by fluorescent multiplex PCR and capillary electrophoresis to reveal the altered copy number in the gene of interest. Data were analyzed with Gene Marker ® software (SoftGenetics). (Fig. 1) .
Data analysis
Since the prevalence of mutations in PARK genes is thought to be higher in young patients, we explored likely associations in a subgroup of 19 patients with EOPD showing particular clinical features, such as tremor 26.3%, mental impairment 5.2% (p < 0.0002 vs. the study group); more frequently prescribed with amantadine (89.5%), antihistamines (78%) and tricyclic acid antidepressants (78.9%) (p < 0.002 vs. the study group); although with similar PD progres sion rate and treatment response (Hoehn & Yahr scale "onstate" = 2.5 ±1.26, p = 0.37; "offstate" = 3.2 ±0.83, p = 0.11; "poor" response 10.5%, p = 0.54). MLPA screening of six PARK genes revealed a deletion of exon 2 in PARK2, the carrier was a female, and she was the youngest patient of this subgroup (30 years old with 2 years of PD symptoms), no tremor or men tal impairment were found, but "poor" response to antiparkinsonian drug therapy was present in this case (LDopa, dopamimetics, anticholinergic and MAO inhibitors). The mutation p.Ala30Pro was also absent in all MLPA screened patients as revealed by the absence of peak signal.
Discussion
Parkinson's disease is a complex neurodegenera tive disorder in which genetic and environmental fac tors are involved. Ethnicity is thought to modify the effect of allelic variants associated to complex dis orders; therefore, searching for prevalent mutations in PARK genes within specific populations is crucial to estimate susceptibility to PD [8] . This holds true especially for LRRK2 gene variants that have shown differential distribution among populations [18] . This also has potential in the pharmacogenetic field; since LRRK2 protein has been proposed as a therapeutic target for PD [4, 41] . Nevertheless, biological mech anisms linking LRRK2 polymorphisms to neurode generation are still unclear. Interestingly, LRRK2 is expressed by immune cells and upregulated follow ing recognition of microbial structures [12] ; allelic var iants in LRRK2 and PARK2, have been associated to leprosy [3] , celiac disease [7] , Crohn's disease [20] and PD [2] ; thus, there is a possible role for the immune system in the neurodegenerative process conferring populationspecific susceptibility for PD.
It is worth mentioning that the highest frequency and penetrance of the LRRK2 p.Gly2019Ser change was found in North African Arabs (NA) and Ashkena zi Jewish (AJ) [13] , in which mitochondrial haplogroup H carrying the m.4336T>C change associated to PD is also common [5] . Interestingly, a high frequency of celiac disease was also described in North Africans [10] . Thus, it is likely that the combination of the A prior study of PARK2 and PD in Mexicanmesti zos showed the absence of homozygous p.Arg366Trp and p.Asp394Asn polymorphisms; interestingly, two polymorphisms p.Ser167Asn and p.Val380Leu were in HWE disequilibrium; authors suggested a compet ing risk of death of variant carriers to explain such finding [23] . We speculate that HWE disequilibrium could be reminiscent evidence of prevalent diseases such as leprosy and tuberculosis in native popula tions of Mexico (http://www.salud.gob.mx/docprog/ estrategia_2/salud_y_nutricion.pdf [20/04/2013] ). This would further support the involvement of PARK genes in immune response, although more indepth research on this matter is required.
Although p.Gly2019Ser and p.Gly2385Arg are commonly found in Caucasians and Asians, respec tively, our study showed a low prevalence on these variants in Mexicanmestizos; similarly to other reports of p.Gly2019Ser in our population [40] and from a population of the South of Spain [24] . This is concordant with the fact that first immigrants who arrived from Europe to Mexico came from the South of Spain [29] . Regarding the p.Gly2385Arg, it remains unexplored in most Latin American populations; here we showed the absence or very low frequen cy of this variant in our group of patients. We also found the p.Gly2385Gly synonymous change and despite it is not linked to PD, pathogenicity could not be excluded; some apparently neutral variants may have an impact on disease development [17] . Our results indicate that p.Gly2019Ser mutation may be a rare cause of PD in patients with different eth nical origin from NA and AJ; especially in the absence of mitochondrial variants associated to PD. Indeed, a recent study in Argentina showed that approximate ly 5.45% (3/55) of PD patients had the p.Gly2019Ser heterozygous change and AJ ancestry, interesting ly one of them presented also celiac disease [7] . Although the frequency of p.Gly2019Ser change was present in two patients and one control, it should be taken into account that the cumulative risk of PD for carriers of that variant is 51% at 69 years old [13] , thus the 66yearold individual from our control group still carries a remaining risk of developing PD. We strongly believe that genetic variants involved in the immune system and neurodegenerative dis eases deserve further exploration. We speculate that the inner toxicity of dopamine production [37] , exposure to pesticides that increase reactive oxygen species [33] , plus increased oxidative stress caused by mitochondrial dysfunction may possibly cause protein oxidation and misfolding, and the subse quent formation of neoepitopes that trigger immune response mediated by LRRK2 and PARK2. Conver gent biological mechanisms and evolutive stories of populations could potentially contribute to elucidate genetic factors influencing PD susceptibility.
With regard of the analysis of the EOPD subgroup, after the screening of six PARK genes, mutation vari ants were rarely identified. However, our results sup port that PARK2 is the most common gene mutated in the EOPD group, and also supports the notion that the lower the age at onset, the more likely a gene mutation can be found in PARK2, as suggest ed by genetic screenings [22] . We cannot rule out a potential influence of the genotype since the patient carrying the PARK2 mutation was the young est one affected of the EOPD subgroup, achieving a limited therapeutic response, although slow clin ical progression. The mechanism responsible for this phenotype may be related to the disruption of the reading frame of PARK2 gene, conferred by the deletion of exon 2 (c.8?_171+?del); and although the deletion was heterozygous, this may be considered a risk factor for PD [25] . Thus, haploinsufficiency in PARKIN production could lead to a hampered turno ver of damaged mitochondrion, due to inappropriate engagement of the autophagy pathway, caused by abnormal interactions between PINK1/PARKIN [39] .
Conclusions
In the Mexicanmestizo population, the p.Gly2019S er change could be a rare case of PD. The combina tion of variants p.Gly2019Ser and m.4336T>C was not present in any case and the p.Gly2385Arg was also absent. To our knowledge, this is the first work exploring the prevalence of pathogenic variants in various PARK genes in the Mexicanmestizo pop ulation. Our data support that PARK2 is the most common gene involved in EOPD and deletion of exon 2 even when heterozygous may be a risk fac tor. Although the most common pathogenic variants were scarce in our population, different nucleotide changes with similar biochemical properties cannot be excluded. The search for populationspecific path ogenic variants in the PARK genes and in other relat ed diseaserelated genes such as SNCA, MAOB, and COMT [37] is important either to elucidate genetic unrevealed risk factors or to provide genetic coun selling and discover novel therapeutic targets for PD.
